Abstract: Ethylene glycol monoethyl ether (EGEE) is known to have testicular toxicity. To elucidate whether EGEE has any effect on sperm motion, especially in the case of short time exposure, we conducted a series of in vivo experiments with rats, as well as an in vitro study with rat sperm. Sperm from cauda epididymides and spermaducts was analyzed for the change in motion with a Hamilton-Thorne Sperm analyzer. Administration of EGEE at 600 mg/kg/d for five weeks significantly decreased total and progressive motility of sperm to 15-30% of controls, in both the cauda epididymis and the spermaduct. The time-course experiment using a single dose of 1,000 mg/ kg showed that damage to sperm motion was evident at 12-24 h after EGEE administration. Addition of EGEE to the medium of sperm had no effect on its motion, but the metabolite ethoxyacetic acid showed a significant inhibitory effect. These results suggest that besides its toxicity to spermatogenesis, the metabolite of EGEE may also directly affect the motion of mature sperm.
Introduction
Ethylene glycol monoethyl ether (EGEE), an organic solvent used for resins, paints and dyes, and as a thinner, has been reported to cause damage in the testes 1, 2) . This was demonstrated by testicular atrophy and decreased sperm count in animals following repeated exposure to the solvent 3, 4) . EGEE is first metabolized to ethoxyacetaldehyde by alcohol dehydrogenase and other enzymes, and further to ethoxyacetic acid by aldehyde dehydrogenase. The initial and major sites of damage following EGEE exposure are believed to be the primary spermatocytes undergoing postzygotene meiotic maturation and division 5) . It is also suspected that it is not EGEE itself, but its metabolites (ethoxyacetic acid, EAA, and possibly ethoxyacetaldehyde) which are responsible for the majority of testicular damage 5, 6) . Sperm count has often been used as the principal parameter for detecting the potential effects of chemicals on spermatozoa. However, it does not always detect adverse After 5 min incubation at 37°C, sperm motion was analyzed using a Hamilton-Thorne Sperm Analyzer (HTM-IVOS, Hamilton Thorn Research, Inc., Beverly, MA, USA). The motion parameters included motility parameters (percentage of motile sperm, percentage of progressively motile sperm), velocity parameters (curvilinear velocity, VCL, average path velocity, VAP, and straight line velocity, VSL), parameter showing the swimming pattern of spermatozoa as head movement (amplitude of lateral head displacement, ALH, and beat cross frequency, BCF), and parameters such as straightness (STR) and linearity (LIN).
In the time-course experiment, rats were treated (p.o.) with a single dose of EGEE at 1,000 mg/kg, and sperm was sampled from the cauda epididymis and spermaduct of left side at 6, 12 and 24 h after administration, and motion analysis was immediately performed as described above.
The effect of EGEE was also studied using an in vitro sperm evaluation system developed for this investigation. Cauda epididymides and spermaducts were removed from unexposed rats, and sperm from the left side was suspended in medium (Medium 199-0.5% BSA) containing EGEE or its metabolite EAA (>98%, Tokyo Kasei, Tokyo) at 10, 20 or 40 µM. For comparison, sperm from the right side was suspended in medium which contained only the same volume of saline. Sperm motion analysis was performed following incubation at 37°C for 10, 20, 30 and 40 min.
Data were analyzed and the significance level was set at p<0.05. For the in vivo experiment data, means were compared among groups for the p value with two-tail analysis of variance, and the data from the in vitro experiments were analyzed as paired data, as control (saline addition) and EAA or EGEE treatment sperm was from the same rat.
Results
Administration of EGEE at the highest dose for five weeks significantly decreased total and progressive motility of sperm from both the cauda epididymis ( Fig. 1 ) and the spermaduct (data not shown) to only 15-30% of controls. The decreases in the lowest and medium dose groups were not significant. Decreased curvilinear velocity (VCL), average path velocity (VAP) and straight line velocity (VSL) were also observed in epididymal sperm, but straightness (STR) and linearity (LIN) remained unchanged (data not shown). The percentage of sperm with rapid motion in the highest dose group was only 21% of the control, while the static sperm was dramatically increased in the highest dose group (Fig. 2) . The ratios of testes to body weight were significantly decreased in the medium and highest dose groups (by 25% and 47%, respectively) after 5 wk treatment with EGEE, while the ratios of prostate and epididymides to body weight were not affected.
In the single dose time-course experiment, abnormal motion of sperm from both the epididymis and spermaduct was detected by decreases in total and progressive motility. The motility of sperm in the EGEE group began to decrease at 6 h (though without significance), and at 12-24 h the motile percentage of sperm had decreased to 60% of controls in the spermaduct (Fig. 3) . The percentage of sperm with rapid velocity significantly declined (Fig. 3) , and that of static sperm rose markedly in the EGEE treatment group (data not shown). These changes were more severe in the spermaduct than in the epididymis. The ratios of testes, prostate and epididymides to body weight were not affected at any time point.
In the in vitro test system, direct addition of EGEE at 10 µM or higher, to the medium of the sperm had no effect on its motion (data not shown). On the other hand, addition of EAA at 10 µM demonstrated an inhibitory effect, and at 30 min the percentages of both motile and progressive sperm from the spermaduct were significantly lower compared to saline (Fig. 4) . The rapid sperm percentage declined with incubation time and at the same time the static sperm increased (data not shown). Addition of EAA at 20 or 40 µM did not show any further inhibitory effects on the sperm motion, possibly implying that 10 µM may be the maximal concentration for this effect.
Discussion
The reproductive toxicity of EGEE has been shown by decreased sperm count and motility after repeated exposure 9, 10) . It is generally believed that the target of EGEE is the testes, resulting in atrophy of the organs, as shown in the 5-wk experiment of this study. Further, histological studies have indicated that dividing spermatocytes are a primary target cell type, and apoptosis may be induced in these cells, resulting in the cessation of spermatogenesis (our unpublished data). As a consequence of all these toxic events in the testes, both the count and motility of sperm are affected.
Spermatogenesis from spermatocytes to spermatozoa, and further to matured sperm, involves a series of processes 11, 12) . The inhibitory effect of EGEE on sperm from the epididymis and spermaduct was observed after 5 wk treatment in this study, and this effect was due, at least in part, to the damage of testes. Did the effect of EGEE on the motility of sperm result only from the pathological processes in the testes, or was there any direct impact of the compound on sperm itself? To answer this question, a time course experiment was conducted, and we found that the inhibitory effect of EGEE began at 6 h following administration and reached the maximal level after 12 h. This effect on sperm from the epididymis and spermaduct was obviously not related to toxic events in the testes, suggesting instead that EGEE treatment directly inhibit the sperm motion.
To confirm this, we established an in vitro test system for estimating the direct effect of chemicals on sperm. EGEE itself did not show any effect on sperm motion at the test concentrations used in the experiments. This is consistent with other reports of animal experiments 5, 6) . However, EAA, the primary metabolite of EGEE, demonstrated an inhibitory effect on sperm motion shown in motile and progressive percentages of sperm, with declined and raised percentages of rapid sperm and static sperm, respectively. This result not only showed that the effect of EGEE on sperm motion is due to the metabolite EAA, but also confirmed the findings of the time course experiment in which EGEE administration directly affected sperm motion. To our knowledge, this is the first report to use an in vitro test system for the evaluation Overall, these results suggest that besides its toxicity to spermatogenesis, EGEE may also affect the motion of mature sperm, while the primary metabolite (EAA) plays some role in the retardation of sperm motion. Detection of sperm motion disorder may therefore be used as an alternative or supplementary measure of sperm toxicity when considering EGEE, especially with short exposure durations. The mechanisms underlying the effect of EGEE on sperm motion need to be further elucidated. Each point represents the mean and SD of 6 assays for 6 rats. *Significantly different from control (p<0.05).
